| 纯度 | >98%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL23R |
| Uniprot No | Q5VWK5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-353aa |
| 氨基酸序列 | GITNINCSGHIWVEPATIFKMGMNISIYCQAAIKNCQPRKLHFYKNGIKE RFQITRINKTTARLWYKNFLEPHASMYCTAECPKHFQETLICGKDISSGY PPDIPDEVTCVIYEYSGNMTCTWNAGKLTYIDTKYVVHVKSLETEEEQQY LTSSYINISTDSLQGGKKYLVWVQAANALGMEESKQLQIHLDDIVIPSAA VISRAETINATVPKTIIYWDSQTTIEKVSCEMRYKATTNQTWNVKEFDTN FTYVQQSEFYLEPNIKYVFQVRCQETGKRYWQPWSSLFFHKTPETVPQVT SKAFQHDTWNSGLTVASISTGHLTSDNRGD |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL23R重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*Structural basis of receptor sharing by interleukin 12 and 23*
**作者**：Hage, C., et al.
**摘要**：该研究通过X射线晶体学解析了IL-23与IL23R/IL12Rβ1受体复合物的三维结构，揭示了IL23R重组蛋白的关键结合域，为靶向IL-23信号通路的药物设计提供了结构基础。
2. **文献名称**：*IL-23 receptor blockade attenuates experimental autoimmune encephalomyelitis by suppressing pathogenic T cell responses*
**作者**：Chen, Y., et al.
**摘要**：利用重组IL23R蛋白作为拮抗剂，在小鼠多发性硬化模型中证明其可通过抑制Th17细胞分化减轻神经炎症，验证了IL23R在自身免疫疾病中的治疗潜力。
3. **文献名称**：*Expression and functional characterization of recombinant human IL-23 receptor in mammalian cells*
**作者**：Wang, X., et al.
**摘要**：研究报道了在HEK293细胞中高效表达功能性IL23R重组蛋白的方法，并通过体外结合实验证实其与IL-23的高亲和力，为相关受体功能研究提供了可靠工具。
4. **文献名称**：*IL-23 signaling promotes tumorigenesis by activating the STAT3 pathway in colorectal cancer*
**作者**：Grivennikov, S., et al.
**摘要**：通过重组IL23R蛋白激活实验，发现IL-23/IL23R信号轴通过STAT3磷酸化驱动结直肠癌细胞增殖，揭示了该受体在肿瘤微环境中的促癌机制。
(注：上述文献信息为示例性质，实际文献需通过PubMed等数据库验证。)
IL23R (Interleukin-23 receptor) is a key component of the interleukin-23 (IL-23) signaling pathway, which plays a pivotal role in mediating inflammatory and immune responses. It is a type I transmembrane protein belonging to the IL-12 receptor family, composed of two subunits: IL23R and IL12RB1. The IL23R subunit is unique to the IL-23 receptor complex, while IL12RB1 is shared with the IL-12 receptor. IL-23. a heterodimeric cytokine comprising p19 and p40 subunits, binds to IL23R with high affinity, triggering downstream signaling events that promote the differentiation and maintenance of Th17 cells. These T-helper cells are critical in host defense but are also implicated in autoimmune and chronic inflammatory diseases, such as psoriasis, inflammatory bowel disease (IBD), and rheumatoid arthritis.
Recombinant IL23R protein is engineered in vitro using expression systems like mammalian cells (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, including glycosylation. This recombinant form retains the extracellular domain’s structural integrity, enabling functional studies of IL-23/IL23R interactions. Researchers utilize IL23R recombinant proteins to investigate receptor-ligand binding kinetics, screen therapeutic inhibitors, and elucidate molecular mechanisms underlying IL-23-driven pathologies. Its application extends to developing monoclonal antibodies or small-molecule drugs targeting the IL-23 pathway, a strategy already validated by FDA-approved biologics like ustekinumab and risankizumab.
Dysregulation of IL-23 signaling is linked to autoimmune disorders, making IL23R a high-priority therapeutic target. Genetic studies have identified IL23R polymorphisms associated with disease susceptibility, highlighting its clinical relevance. Recombinant IL23R tools thus serve as vital resources for both basic research and drug discovery, bridging molecular insights to therapeutic innovations in immune-mediated diseases.
×
